Fig. 2

Incidence plots and Time-Gain curves for PROVE-IT (4p-MACE), LIFE (3p-MACE) and HOPE (3p-MACE) trials. 4p-MACE* outcome: death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting—if these procedures were performed at least 30 days after randomization—and stroke; 3p-MACE outcome: cardiovascular death, non-fatal stroke and non-fatal myocardial infarction), a Incidence plots in the PROVE-IT (blue line: pravastatin 40 mg, red line: atorvastatin 80 mg), LIFE (blue line: atenolol, red line: losartan) and HOPE (blue line: placebo, red line: ramipril) studies. b Observed Time-Gain curves (continuous line) throughout the duration of the three studies and fitted Time-Gain curves (f50%; dotted lines) with the extrapolation beyond time at which less than 50% of the cohort was in follow-up (indicated by arrows) for PROVE-IT and LIFE trials. For the HOPE trial (due to the absence of data of population in follow-up), the fit and the extrapolation were performed beyond half the duration of the trial (indicated by arrows)